RCUS (Arcus Biosciences) FFO


RCUS Arcus Biosciences Inc RCUS
46 GF Score
Price $28.80
GF Value $13.85
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Arcus Biosciences FFO?

FFO (Funds from operations) only applies to REITs.

RCUS
46GF Score
Arcus Biosciences Inc RCUS
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Arcus Biosciences (RCUS) Overvalued in 2026?

Based on GuruFocus' analysis, Arcus Biosciences stock appears to be overvalued. The current stock price of $28.80 is trading 107.9% above its estimated GF Value™ of $13.85. GuruFocus considers Arcus Biosciences to be Significantly Overvalued.

Key valuation signals for RCUS:

  • FFO:
  • GF Value™: $13.85 vs. price of $28.80 (107.9% above fair value)
  • GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the RCUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arcus Biosciences Business Description

Address 3928 Point Eden Way, Hayward, CA, USA, 94545
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
46GF Score

Get the complete analysis for RCUS

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.80
Price
$13.85
GF Value